Oleolive Inc was awarded Phase 2 STTR funding from the National Institute on Aging to study a novel drug to treat Alzheimer’s Disease

Oleolive Inc’s grant application “Evaluation of a dual PPAR agonist for treatment of Alzheimer’s Disease” was approved for funding. Alzheimer’s disease (AD) and AD related dementias (ADRD) constitute a major public health problem and there are only a few FDA approved treatments that provide meaningful benefit in halting these diseases. This Phase II project is designed to support data from Phase I, which demonstrated OL-003 is safe and effective, by further evaluating OL-003 efficacy in two additional animal models and performing pharmacology and toxicology studies. These data are required by the FDA to file an IND to initiate Phase I clinical trials that could lead to approval of OL-003 as an AD therapeutic. This is a joint effort between Auburn and Oleolive.